Trial Profile
A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Sep 2022
Price :
$35
*
At a glance
- Drugs Odetiglucan (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Aug 2022 Planned End Date changed from 1 Sep 2021 to 1 Oct 2025.
- 14 Sep 2021 Primary endpoint has not been met. (Phase II: Progression Free Survival), as per Results presented at the 2021 World Conference on Lung Cancer
- 14 Sep 2021 The protocol has been amended to allow patients who previously received ICI after its approval in the 1st line setting